menu
    • menu
    [{"orgOrder":0,"company":"Medtronic Plc","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"Insulin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Medtronic Plc","amount2":0.34000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0.34000000000000002,"dosageForm":"Capsule","sponsorNew":"Medtronic Plc \/ Blackstone Life Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Medtronic Plc \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Medtronic Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Insulin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Medtronic Plc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medtronic Plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Medtronic Plc \/ Not Applicable"},{"orgOrder":0,"company":"Medtronic Plc","sponsor":"Intersect ENT","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Mometasone Furoate","moa":"NF-?B","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Medtronic Plc","amount2":1.1000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":1.1000000000000001,"dosageForm":"Implant","sponsorNew":"Medtronic Plc \/ Medtronic","highestDevelopmentStatusID":"12","companyTruncated":"Medtronic Plc \/ Medtronic"},{"orgOrder":0,"company":"Medtronic Plc","sponsor":"Intersect ENT","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Mometasone Furoate","moa":"Corticosteroid","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Medtronic Plc","amount2":1.1000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":1.1000000000000001,"dosageForm":"","sponsorNew":"Medtronic Plc \/ Medtronic","highestDevelopmentStatusID":"12","companyTruncated":"Medtronic Plc \/ Medtronic"},{"orgOrder":0,"company":"Medtronic Plc","sponsor":"Arecor","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Insulin","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Medtronic Plc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Medtronic Plc \/ Medtronic Plc","highestDevelopmentStatusID":"4","companyTruncated":"Medtronic Plc \/ Medtronic Plc"}]

    Find Clinical Drug Pipeline Developments & Deals by Medtronic Plc

    Menu

    Medtronic Plc

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Medtronic Plc

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Medtronic Plc

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Recipient : Arecor

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Arecor and Medtronic Collaborate to Develop Novel Thermostable Insulin for Pump Delivery

                            Details : The collaboration aims to develop a novel, high concentration, thermostable insulin for use by Medtronic’s Diabetes business in a next-generation implantable pump.

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            May 09, 2024

                            Lead Product(s) : Insulin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Recipient : Arecor

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Medtronic Plc

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Medtronic Plc

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mometasone Furoate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Approved

                            Recipient : Intersect ENT

                            Deal Size : $1,100.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Medtronic Completes Acquisition of Intersect ENT

                            Details : Medtronic has acquired Intersect ENT's PROPEL™ and SINUVA™ (mometasone furoate) sinus implant product lines and technology, intellectual property, and Menlo Park, Calif., facility.

                            Brand Name : Propel

                            Molecule Type : Small molecule

                            Upfront Cash : $1,100.0 million

                            May 13, 2022

                            Lead Product(s) : Mometasone Furoate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Approved

                            Recipient : Intersect ENT

                            Deal Size : $1,100.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Medtronic Plc

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Medtronic Plc

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mometasone Furoate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Approved

                            Recipient : Intersect ENT

                            Deal Size : $1,100.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Medtronic to Acquire Intersect ENT

                            Details : Intersect ENT's PROPEL® and SINUVA® sinus implants are clinically proven solutions that open sinus passageways and deliver an anti-inflammatory steroid to aid in healing.

                            Brand Name : Propel

                            Molecule Type : Small molecule

                            Upfront Cash : $1,100.0 million

                            August 06, 2021

                            Lead Product(s) : Mometasone Furoate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Approved

                            Recipient : Intersect ENT

                            Deal Size : $1,100.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Medtronic Plc

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Medtronic Plc

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Medtronic Announces FDA Approval for Minimed™ 770G Insulin Pump System with Smartphone Connectivity for Peop...

                            Details : The 770G System is a first-of-a-kind device for patients aged 2 to 6 years. It is the first legally marketed device that can automatically adjust insulin delivery based on continuous glucose monitor values for this patient population.

                            Brand Name : MiniMed 770G

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            September 01, 2020

                            Lead Product(s) : Insulin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Medtronic Plc

                            U.S.A arrow
                            PackExpo
                            Not Confirmed

                            Medtronic Plc

                            U.S.A arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Blackstone Life Sciences

                            Deal Size : $337.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Medtronic Announces a $337 Million Product Investment from Blackstone Life Sciences to Expand Development of F...

                            Details : Funding will support Medtronic's Diabetes R&D, including a series of near-term programs such as the MiniMed™ 780G insulin pump system, its Personalized Closed Loop (PCL) system, extended wear infusion set, and Zeus and Synergy sensors.

                            Brand Name : MiniMed 780G

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            June 12, 2020

                            Lead Product(s) : Insulin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Blackstone Life Sciences

                            Deal Size : $337.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth